Lonza Group


04/01/19 -"We have factored in more details for the divestment of the Water Treatment business and have made additional adjustments for 2018, 2019 and the following year. We have removed the extra income from ..."

Pages
53
Language
English
Published on
04/01/19
You may also be interested by these reports :
17/07/19
Genmab’s collaboration partner, J&J, has released better than expected sales numbers for Darzalex for Q2, but the beat was largely due to one-off ...

09/07/19
The agricultural business in North America is burdened by two adverse effects: unfavourable weather conditions and Trumpism. The former was ...

05/07/19
June was a good month for pharmas. In the last one month (to 4 July 2019), the sector has outperformed the broader market marginally, helped by a ...

18/06/19
Ipsen (Buy, France) was cruising swiftly when we last teased about it a year ago. While label expansion (approval in first-line) for the kidney ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO